

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:sssptal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Dec 17	The CA Lexicon available in the CAPLUS and CA files
NEWS 3	Feb 06	Engineering Information Encompass files have new names
NEWS 4	Feb 16	TOXLINE no longer being updated
NEWS 5	Apr 23	Search Derwent WPINDEX by chemical structure
NEWS 6	Apr 23	PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
NEWS 7	May 07	DGENE Reload
NEWS 8	Jun 20	Published patent applications (A1) are now in USPATFULL
NEWS 9	JUL 13	New SDI alert frequency now available in Derwent's DWPI and DPCI
NEWS 10	Aug 23	In-process records and more frequent updates now in MEDLINE
NEWS 11	Aug 23	PAGE IMAGES FOR 1947-1966 RECORDS IN CAPLUS AND CA
NEWS 12	Aug 23	Adis Newsletters (ADISNEWS) now available on STN
NEWS 13	Sep 17	IMSworld Pharmaceutical Company Directory name change to PHARMASEARCH
NEWS 14	Oct 09	Korean abstracts now included in Derwent World Patents Index
NEWS 15	Oct 09	Number of Derwent World Patents Index updates increased
NEWS 16	Oct 15	Calculated properties now in the REGISTRY/ZREGISTRY File
NEWS 17	Oct 22	Over 1 million reactions added to CASREACT
NEWS 18	Oct 22	DGENE GETSIM has been improved
NEWS 19	Oct 29	AAASD no longer available
NEWS EXPRESS	August 15	CURRENT WINDOWS VERSION IS V6.0c, CURRENT MACINTOSH VERSION IS V6.0 (ENG) AND V6.0J (JP), AND CURRENT DISCOVER FILE IS DATED 07 AUGUST 2001
NEWS HOURS		STN Operating Hours Plus Help Desk Availability
NEWS INTER		General Internet Information
NEWS LOGIN		Welcome Banner and News Items
NEWS PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:17:50 ON 12 NOV 2001

=> file medline, agricola, biosis, embase, dgene, uspat, hcaplus, wpids, japio, jicst, fsta, frosti, biotechds

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'MEDLINE' ENTERED AT 14:18:30 ON 12 NOV 2001

FILE 'AGRICOLA' ENTERED AT 14:18:30 ON 12 NOV 2001

FILE 'BIOSIS' ENTERED AT 14:18:30 ON 12 NOV 2001
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'EMBASE' ENTERED AT 14:18:30 ON 12 NOV 2001
COPYRIGHT (C) 2001 Elsevier Science B.V. All rights reserved.

FILE 'DGENE' ENTERED AT 14:18:30 ON 12 NOV 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'USPATFULL' ENTERED AT 14:18:30 ON 12 NOV 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'HCAPLUS' ENTERED AT 14:18:30 ON 12 NOV 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 14:18:30 ON 12 NOV 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'JAPIO' ENTERED AT 14:18:30 ON 12 NOV 2001
COPYRIGHT (C) 2001 Japanese Patent Office (JPO)

FILE 'JICST-EPLUS' ENTERED AT 14:18:30 ON 12 NOV 2001
COPYRIGHT (C) 2001 Japan Science and Technology Corporation (JST)

FILE 'FSTA' ENTERED AT 14:18:30 ON 12 NOV 2001
COPYRIGHT (C) 2001 International Food Information Service

FILE 'FROSTI' ENTERED AT 14:18:30 ON 12 NOV 2001
COPYRIGHT (C) 2001 Leatherhead Food Research Association

FILE 'BIOTECHDS' ENTERED AT 14:18:30 ON 12 NOV 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

=> s fibrinogen

L1 125676 FIBRINOGEN

=> s l1 and separation () human blood plasma

5 FILES SEARCHED...

L2 0 L1 AND SEPARATION (W) HUMAN BLOOD PLASMA

=>

=> s l1 and separation

L3 3467 L1 AND SEPARATION

=> s 13 and method

L4 2462 L3 AND METHS

=> s 14 and antihaemophilic factor

L5 9 L4 AND ANTIHAEMOPHILIC FACTOR

=> d 15 ti abs ibib tot

L5 ANSWER 1 OF 9 USPATFULL

TI **Method** for high loading of vesicles with biopolymeric substances

AB A **method** for loading liposomes with biopolymeric substances functional in humans involves combining a physiologically compatible solution of the biopolymeric substances with one or more dry, liposome-forming lipids, effecting a lipid-containing fraction, combining the lipid-containing fraction with an organic solvent, effecting an organic solvent fraction, and drying the organic solvent fraction, which effects a dry fraction of liposomes loaded with the biopolymeric substances.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:164097 USPATFULL

TITLE: **Method** for high loading of vesicles with biopolymeric substances

INVENTOR(S): Barenholz, Yechezkel, Jerusalem, Israel
Nur, Israel, Tel Aviv, Israel
Bar, Lilianne K., Rehovot, Israel
Diminsky, Dvorah, Jerusalem, Israel
Baru, Moshe, Pardes-Hanna, Israel

PATENT ASSIGNEE(S): Opperbas Holding B.V., Amsterdam Zuidoost, Netherlands (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6156337		20001205
APPLICATION INFO.:	US 1996-709679		19960909 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 591538		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kishore, Gollamudi S.		
LEGAL REPRESENTATIVE:	Jacobson, Price, Holman & Stern, PLLC		
NUMBER OF CLAIMS:	36		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 8 Drawing Page(s)		
LINE COUNT:	1239		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 9 USPATFULL

TI Process for the manufacture of very high-purity antithaemophilic factor (FVIIIc), and von Willebrand factor, and pharmaceutical compositions containing same

AB The invention relates to a process for the manufacture of very high-purity antihemophilic factor (FVIIIc) and von Willebrand factor. This process enables the manufacture of very high-purity antihemophilic factor (FVIIIc) devoid of the bulk of the Willebrand factor comprises a step for purification by ion exchange chromatography with the aid of a chromatography column containing a gel, the purification step comprising
a step for adsorption of the antihemophilic factor essentially devoid of
the Willebrand factor on the gel in the column and a step for
desorption

of the purified antihemophilic factor, which is collected, thereby obtaining an antihemophilic factor devoid of the bulk of the Willebrand factor and having a activity as high as 250 IU/mg of proteins. This process also permits to recover von Willebrand factor in very high purity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:61796 USPATFULL
 TITLE: Process for the manufacture of very high-purity antithaemophilic factor (FVIIIc), and von Willebrand factor, and pharmaceutical compositions containing same
 INVENTOR(S): Dazey, Bernard, Bordeaux, France
 Hamsany, Mohamed, Bordeaux, France
 Vezon, Gerard, Cursan, France
 PATENT ASSIGNEE(S): Association d'Aquitaine pour de Developpment de la Transfusion Sanguine et des Recherches Hematologiques, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5760183		19980602
APPLICATION INFO.:	US 1993-16807		19930211 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1990-476978, filed on 7 Feb 1990, now abandoned And Ser. No. US 1991-739452, filed on 2 Aug 1991, now patented, Pat. No. US 5252710		

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1989-2136	19890217
	FR 1990-9917	19900802
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Russel, Jeffrey E.	
LEGAL REPRESENTATIVE:	Londa and Traub LLP	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1	
LINE COUNT:	881	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 9 USPATFULL

TI **Method** for isolating factors VIII from plasma by gel filtration chromatography under group **separation** conditions
 AB A **method** for isolating Factor VIII from other proteins dissolved in blood plasma is disclosed, wherein plasma is subjected to gel filtration under group **separation** conditions giving a fraction containing Factor VIII in very high yield and almost free of other proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 93:76632 USPATFULL
 TITLE: **Method** for isolating factors VIII from plasma by gel filtration chromatography under group **separation** conditions
 INVENTOR(S): Kaersgaard, Per, Vedbaek, Denmark
 PATENT ASSIGNEE(S): Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5245014		19930914
APPLICATION INFO.:	US 1990-610480		19901107 (7)

	NUMBER	DATE
PRIORITY INFORMATION:	1989-5621	19891109
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Wax, Robert A.	
ASSISTANT EXAMINER:	Ekstrom, Richard C.	
LEGAL REPRESENTATIVE:	Zelson, Steve T., Lambiris, Elias J.	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	598	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 9 USPATFULL

TI Protein C activator, methods of preparation and use thereof

AB A **method** and composition for assaying protein C is described.
The **method** comprises reacting a protein C-containing medium
with a protein C-activating activator preparation obtained from venom
of
the snake Agkistrodon contortrix, or venom of another snake species
which undergoes an immunological cross-reaction with the venom of
Agkistrodon contortrix, to cause maximum activation of protein C and
subsequently determining the quantity of activated protein C, said
quantity being proportional to the amount of protein C in said medium.
Also disclosed is a **method** and composition for treating
thrombotic disorders with the activator preparation and a **method**
of obtaining the activator preparation by culturing of a cloned
microorganism.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 89:58713 USPATFULL

TITLE: Protein C activator, methods of preparation and use
thereof

INVENTOR(S): Stocker, Kurt F., Aesch, Switzerland
Svendsen, Lars G., Reinach, Switzerland

PATENT ASSIGNEE(S): Pentapharm AG, Basel, Switzerland (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4849403		19890718
APPLICATION INFO.:	US 1986-861786		19860509 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1985-2267	19850529
	CH 1985-413584	19850925
	CH 1985-5087	19851128
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Rosen, Sam	
LEGAL REPRESENTATIVE:	Pennie & Edmonds	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1,3	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	891	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 9 USPATFULL

TI Purification of blood coagulation factor VIII by precipitation with
sulfated polysaccharides

AB Efficient precipitation and removal of the proteins **fibrinogen**
and fibronectin from blood plasma fractions, especially
cryoprecipitate,

while leaving high yields of blood coagulation factor VIII in the supernatant. This is achieved by the addition of at least 0.15 mg, preferably 0.3-0.9 mg, of a sulphated polysaccharide especially heparin, per ml of buffered plasma fraction solution while maintaining the temperature of the solution during fibrinogen/fibronectin removal at more than 15.degree. C., preferably 20.degree.-35.degree. C. Lyophilised factor VIII preparation prepared from the factor VIII-rich supernatant product of the invention are suitable for heat treatment

at,

for example, 70.degree. C. for 24 hours to inactivate blood-born viruses without significant generation of insoluble denatured protein by-products.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 88:79161 USPATFULL
 TITLE: Purification of blood coagulation factor VIII by precipitation with sulfated polysaccharides
 INVENTOR(S): Winkelman, Lowell, Oxford, England
 PATENT ASSIGNEE(S): The Central Blood Laboratories Authority, Borehamwood, England (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4789733		19881206
	WO 8605190		19860912
APPLICATION INFO.:	US 1986-928178		19861117 (6)
	WO 1986-GB121		19860306
			19861117 PCT 371 date
			19861117 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1985-5882	19850307
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Schain, Howard E.	
LEGAL REPRESENTATIVE:	Nixon & Vanderhye	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
LINE COUNT:	692	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 9 USPATFULL

TI Blood fractionation improvement

AB The extraction of Factor VIII, the **antihaemophilic**

factor in blood, is difficult due to its instability and the presence of impurities. An initial Factor VIII containing aqueous solution such as blood plasma is purified by subjecting a Factor VIII containing aqueous migrant solution to continuous flow electrophoresis wherein flow takes place in an annular **separation** chamber and is stabilized by means of an angular velocity gradient; and collecting

a

separated Factor VIII component.

In order to separate the Factor VIII from albumin and fibrinogen,

while

obtaining good recoveries of Factor VIII (e.g. about 60%), the migrant solution is prepared by precipitating Factor VIII from the initial solution using ethanol, and removing and redissolving the precipitate

in

an aqueous medium and adjusting the pH to be within the range of 7.5 to 8.6, preferably 8.3 to 8.6.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 81:45396 USPATFULL

TITLE: Blood fractionation improvement

INVENTOR(S): Mattock, Patrick, Oxford, England
Aitchison, Gordon F., Abingdon, England

PATENT ASSIGNEE(S): United Kingdom Atomic Energy Authority, London,
England

(non-U.S. government)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4465574		19840814
APPLICATION INFO.:	US 1982-362662		19820329 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1981-11056	19810408
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Tufariello, T. M.	
ASSISTANT EXAMINER:	Williams, T.	
LEGAL REPRESENTATIVE:	Larson and Taylor	
NUMBER OF CLAIMS:	3	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	262	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 9 USPATFULL

TI Purification of Factor VIII

AB PCT No. PCT/GB78/00038 Sec. 371 Date June 22, 1979 Sec. 102(e) Date
June

22, 1979, PCT Filed Nov. 10, 1978 PCT Pub. No. WO 79/00299 PCT Pub.
Date
May 31, 1979.

The invention is concerned with purification of Factor VIII containing solutions, such as blood plasma, by continuous flow electrophoresis.

Hitherto, purification of such solutions has been performed by methods such as cryoprecipitation which however have the disadvantages of poor recovery. In our invention, this problem is overcome by adjusting the pH of a Factor VIII containing solution to be in a range where the stability of Factor VIII is not adversely affected (e.g. 6 to 9) and then subjecting the solution to continuous flow electrophoresis to give purified Factor VIII fractions. If desired, the fractions may be further purified.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 81:7826 USPATFULL

TITLE: Purification of Factor VIII

INVENTOR(S): Mattock, Patrick, Botley, England

PATENT ASSIGNEE(S): United Kingdom Atomic Energy Authority, London,
England

(non-U.S. government)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4250008		19810210
APPLICATION INFO.:	US 1979-112633		19790622 (6)

NUMBER	DATE
--------	------

PRIORITY INFORMATION: (G) 1977-47933 19771117
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Prescott, Arthur C.
LEGAL REPRESENTATIVE: Larson, Taylor and Hinds
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 211
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 9 USPATFULL

TI **Method** of producing a blood-coagulation-promoting preparation from human blood plasma
AB In a **method** of producing a blood-coagulation-promoting preparation from human blood plasma, which preparation contains a new blood-coagulating substance called "FEIBA", human plasma with citrate ions is treated with water-insoluble inorganic coagulation-physiologically-surface-active substances in the absence of free calcium ions, thus generating "FEIBA", the water-insoluble substances are separated, the supernatant is treated with basic ion exchangers, wherein "FEIBA" and the coagulation factors II-VII-IX-X adhere to the ion exchangers, and "FEIBA" and the factors II-VII-IX-X are eluted and concentrated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 79:29942 USPATFULL
TITLE: **Method** of producing a blood-coagulation-promoting preparation from human blood plasma
INVENTOR(S): Eibl, Johann, Vienna, Austria
Schwarz, Otto, Vienna, Austria
Elsinger, Fritz, Vienna, Austria
PATENT ASSIGNEE(S): Immuno Aktiengesellschaft fur chemisch-medizinische Produkte, Vienna, Austria (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4160025		19790703
APPLICATION INFO.:	US 1977-822679		19770808 (5)

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1976-6405	19760830
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Rosen, Sam	
LEGAL REPRESENTATIVE:	Brumbaugh, Graves, Donohue & Raymond	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
LINE COUNT:	603	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 9 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD

TI Highly purified anti haemophilic factor prepn. - using sepn. on basis of Stoke radius.
AN 1984-075332 [13] WPIDS
AB AU 8317472 A UPAB: 19930925
Homogeneous **Antihæmophilic Factor** (AHF) concentrate is prepd. by (a) obtaining an AHF concentrate which is totally or partially free from prothrombin complex proteins, **fibrinogen** and albumin, (G) subjecting the concentrate to a sepn. on the basis of Stoke's radius to separate AHF of on apparently high Stoke's radius value

from other protein, (c) treating the concentrate to change the effective Stoke's radius of the AHF molecule to an apparently low value, (d) subjecting the concentrate to a sepn. as in (b) to separate AHF of apparently low Stoke's radius value from other proteins, and (e) subjecting the concentrate to chromatography on an anion exchange medium to obtain the required product.

Dried preps. of AHF concentrate are administered to haemophiliacs for treatment of bleeding or in advance of surgery, and it is desirable that the concentrate be as pure as possible. The present process provides a concentrate having about 4000-8000 units of AHF (procoagulant) activity per mg. of protein (one unit of activity is that found in 1 ml. of normal human plasma), whereas known concentrates only have activity of up to about 10 units per mg. The present product appears to be homogeneous and to have a mol.wt. of 200,000-400,000 daltons by HPLC.

0/5

ABEQ EP 104356 B UPAB: 19930925

A **method** for preparing a highly purified, essentially homogeneous Antihemophilic Factor concentrate, characterised in that it comprises the steps of: (a) obtaining an Antihemophilic Factor concentrate

which is totally or partially free from prothrombin complex proteins, **fibrinogen**, and albumin, (b) subjecting the Antihemophilic Factor concentrate to a **separation** on the basis of Stoke's radius to separate Antihemophilic Factor of an apparently high Stoke's radius value from other proteins, (c) treating the Antihemophilic Factor concentrate to

change the effective Stoke's radius of the Antihemophilic Factor molecule to an apparently low value, (d) subjecting the Antihemophilic Factor concentrate to a **separation** on the basis of Stoke's radius to separate Antihemophilic Factor of apparently low Stoke's radius value from

other proteins, (e) subjecting the Antihemophilic Factor concentrate to chromatography on an anion exchange medium.

ABEQ US 4495175 A UPAB: 19930925

Highly purified, homogeneous Antihemophilic Factor concentrate is prepd. by (a) obtaining an Antihemophilic Factor concentrate (I) which is totally

or partially free from prothrombin complex proteins, **fibrinogen** and albumin; (b) subjecting (I) to a sepn. on the basis of Stokes radius to separate Antihemophilic Factor of an apparently high Stokes radius value from other proteins; (c) treating (I) to change the effective

Stokes radius of the Antihemophilic Factor mol. to an apparently low value; (d) subjecting (I) to a sepn. on the basis of Stokes radius to separate Antihemophilic Factor of apparently low Stokes radius value from other proteins; (e) subjecting (I) to chromatography on an anion exchange

medium to yield a highly purified, homogeneous Factor VIIIC characterised by a specific activity of at least 4000 being free of **fibrinogen** and von Willebrand's protein, and single band electrophoretic mobility on SDS/PAGE at an apparent mol. wt. around 100,000 daltons.

ADVANTAGE - Human AHF prepn. of high purity and high activity is obtd.

ACCESSION NUMBER: 1984-075332 [13] WPIDS

DOC. NO. CPI: C1984-032475

TITLE: Highly purified anti haemophilic factor prepn. - using sepn. on basis of Stoke radius.

DERWENT CLASS: B04

INVENTOR(S): CHAVIN, S I; FAY, P J

PATENT ASSIGNEE(S): (MILE) MILES LAB INC; (UYRP) UNIV ROCHESTER; (UYRO) UNIV ROST

COUNTRY COUNT: 10

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
AU 8317472	A	1984-09	(198413)*		31
EP 104356	A	19840404	(198415)	EN	
R: DE FR GB IT SE					
JP 59044322	A	19840312	(198416)		
US 4495175	A	19850122	(198506)		
ES 8501979	A	19850316	(198523)		
CA 1213214	A	19861028	(198648)		
EP 104356	B	19870114	(198702)	EN	
R: DE FR GB IT SE					
DE 3369143	G	19870219	(198708)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
AU 8317472	A	AU 1983-17472	19830801
EP 104356	A	EP 1983-107420	19830728
JP 59044322	A	JP 1983-131256	19830803
US 4495175	A	US 1982-405456	19820805

PRIORITY APPLN. INFO: US 1982-405456 19820805; US 1984-570728
19840113

=> d his

(FILE 'HOME' ENTERED AT 14:17:50 ON 12 NOV 2001)

FILE 'MEDLINE, AGRICOLA, BIOSIS, EMBASE, DGENE, USPATFULL, HCAPLUS, WPIDS, JAPIO, JICST-EPLUS, FSTA, FROSTI, BIOTECHDS' ENTERED AT 14:18:30 ON 12 NOV 2001

L1 125676 S FIBRINOGEN
L2 0 S L1 AND SEPARATION () HUMAN BLOOD PLASMA
L3 3467 S L1 AND SEPARATION
L4 2462 S L3 AND METHOD
L5 9 S L4 AND ANTIHAEMOPHILIC FACTOR

=> s sulphated polysaccharide

L6 386 SULPHATED POLYSACCHARIDE

=> s l6 and precipitate

L7 23 L6 AND PRECIPITATE

=> d l7 ti abs ibib tot

L7 ANSWER 1 OF 23 USPATFULL
TI 49 human secreted proteins
AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:155766 USPATFULL

TITLE: 49 human secreted proteins
 INVENTOR(S): More, Paul A., Germantown, MD, United States
 Rosen, Steven M., Oley, MD, United States
 Olsen, Henrik S., Gaithersburg, MD, United States
 Shi, Yanggu, Gaithersburg, MD, United States
 Rosen, Craig A., Laytonsville, MD, United States
 Florence, Kimberly A., Rockville, MD, United States
 Soppet, Daniel R., Centreville, VA, United States
 Lafleur, David W., Washington, DC, United States
 Endress, Gregory A., Potomac, MD, United States
 Ebner, Reinhard, Gaithersburg, MD, United States
 Komatsoulis, George, Silver Spring, MD, United States
 Duan, Roxanne D., Bethesda, MD, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001021700	A1	20010913
APPLICATION INFO.:	US 2000-739254	A1	20001219 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-511554, filed on 23 Feb 2000, ABANDONED Continuation-in-part of Ser. No.		

WO 1999-US19330, filed on 24 Aug 1999, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-97917	19980825 (60)
	US 1998-98634	19980831 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
LINE COUNT:	15462	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L7 ANSWER 2 OF 23 USPATFULL
 TI Fibres of cospun alginates
 AB Fibres which are useful in wound dressings comprising an alginate co-spun with at least one water soluble organic polymeric species (other than an alginate). Examples of such fibers comprise alginate and CMC.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 ACCESSION NUMBER: 2000:80428 USPATFULL
 TITLE: Fibres of cospun alginates
 INVENTOR(S): Qin, Yimin, Northwich, United Kingdom
 Gilding, Denis Keith, Winsford, United Kingdom
 PATENT ASSIGNEE(S): Advanced Medical Solutions Limited, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6080420		20000627
	WO 9610106		19960404
APPLICATION INFO.:	US 1997-809686		19970630 (8)
	WO 1995-GB2284		19950926
			19970630 PCT 371 date
			19970630 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1994-19572	19940929
	GB 1995-1514	19950126

GB 1995-16930 19950818
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Bawa, R.
LEGAL REPRESENTATIVE: Browning, Clifford W. Woodard, Emhardt, Naughton,
Moriarty & McNett Patent and Trademark Attorneys
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
LINE COUNT: 263
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 23 USPATFULL

TI Drug salts

AB It has been found that sugar acid salts represent beneficial controlled release forms for basic organic drug compounds. Examples of appropriate salts include mono, di, oligo and polysaccharide poly-O-sulphonic acid salts of antibiotics such as tetracyclins and aminoglycosides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:77338 USPATFULL

TITLE: Drug salts

INVENTOR(S): Dyrsting, Hjarne, Virum, Denmark
Koch, Torben, Copenhagen, Denmark

PATENT ASSIGNEE(S): Dumex-Alpha A/S, Copenhagen, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6077822		20000620
APPLICATION INFO.:	US 1995-402619		19950313 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-141625, filed on 27 Oct 1993, now patented, Pat. No. US 5595977 And		
a	continuation-in-part of Ser. No. US 1994-265193, filed on 24 Jun 1994, now patented, Pat. No. US 5538954 And		
a	continuation-in-part of Ser. No. WO 1994-DK341, filed on 13 Sep 1994		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1993-1034	19930914
	DK 1994-667	19940610
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Peselev, Elli	
LEGAL REPRESENTATIVE:	Watov & Kipnes, P.C.	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	17	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	1639	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L7 ANSWER 4 OF 23 USPATFULL

TI Anti-angiogenic Compositions and methods for the treatment of arthritis

AB The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples

of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:155724 USPATFULL

TITLE: Anti-angiogenic Compositions and methods for the treatment of arthritis

INVENTOR(S): Hunter, William L., Vancouver, Canada
Machan, Lindsay S., Vancouver, Canada
Arsenault, A. Larry, Paris, Canada

PATENT ASSIGNEE(S): Angiogenesis Technologies, Inc., Vancouver, Canada
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5994341		19991130
APPLICATION INFO.:	US 1995-478914		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-417160, filed on 3 Apr 1995, now abandoned which is a continuation-in-part of Ser. No. US 1993-94536, filed on 19 Jul 1993, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1994-CA373	19940719
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Kumar, Shailendra	
LEGAL REPRESENTATIVE:	Seed & Berry LLP	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	129 Drawing Figure(s); 75 Drawing Page(s)	
LINE COUNT:	5044	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 23 USPATFULL

TI Anti-angiogenic compositions and methods of use

AB The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples

of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1999:37140 USPATFULL

TITLE: Anti-angiogenic compositions and methods of use

INVENTOR(S): Hunter, William L., Vancouver, Canada
Machan, Lindsay S., Vancouver, Canada
Arsenault, A. Larry, Paris, Canada

PATENT ASSIGNEE(S): Angiotech Pharmaceuticals Inc., Vancouver, Canada
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5886026		19990323
APPLICATION INFO.:	US 1995-472413		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-417160, filed on 3 Apr 1995, now abandoned which is a continuation-in-part of Ser. No. US 1993-94536, filed on 19 Jul 1993, now abandoned		

NUMBER	DATE
--------	------

PRIORITY INFORMATION: WO 1994-CA373 19940719
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kumar, Shailendra
LEGAL REPRESENTATIVE: Seed and Berry LLP
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 130 Drawing Figure(s); 75 Drawing Page(s)
LINE COUNT: 4997
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 23 USPATFULL

TI Anti-angiogenic compositions and methods of use

AB The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples

of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:14828 USPATFULL
TITLE: Anti-angiogenic compositions and methods of use
INVENTOR(S): Hunter, William L., Vancouver, Canada
Machan, Lindsay S., Vancouver, Canada
Arsenault, A. Larry, Paris, Canada
PATENT ASSIGNEE(S): Angiogenesis Technologies, Inc., Vancouver, Canada
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5716981		19980210
APPLICATION INFO.:	US 1995-478203		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-417160, filed on 3 Apr 1995, now abandoned which is a continuation-in-part of Ser. No. US 1993-94536, filed on 19 Jul 1993, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1994-CA373	19940719
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Kumar, Shailendra	
LEGAL REPRESENTATIVE:	Seed and Berry LLP	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	130 Drawing Figure(s); 75 Drawing Page(s)	
LINE COUNT:	5084	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 23 USPATFULL

TI Anti-inflammatory compounds and compositions

AB A method for inactivating viruses which comprises the step of contacting

the virus with an effective amount of a substantially pure divalent metal ion chelate of a polysulfate of xylan having glycosidically linked

D-glucuronyl side chains with divalent metal ions chelated thereto wherein substantially all monovalent ions have been substituted by divalent metal ions, said divalent metal ions being selected from the group consisting of Ca.sup.2+, Mg.sup.2+, Cu.sup.2+ and Zn.sup.2+.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 96:3943 USPATFULL

TITLE: Anti-inflammatory compounds and compositions

INVENTOR(S): Cullis-Hill, David, Bondi Junction, Australia
Ghosh, Peter, Fairlight, Australia

PATENT ASSIGNEE(S): Anthropharm Pty. Limited, Bondi Junction, Australia
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5668116		19970916
APPLICATION INFO.:	US 1996-613535		19960311 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-182541, filed on 18 Jan 1994, now abandoned which is a		
continuation-in-part	of Ser. No. US 1993-71277, filed on 4 Jun 1993, now abandoned which is a division of Ser. No. US 1992-903081, filed on 10 Jun 1992, now patented, Pat. No. US 5470840 which is a division of Ser. No. US 1989-423455, filed on 19 Sep 1989, now patented, Pat. No. US 5145841		

	NUMBER	DATE
PRIORITY INFORMATION:	AU 1987-10951	19870319
	AU 1987-12478	19870615
	AU 1987-915819	19871209
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Peselev, Elli	
LEGAL REPRESENTATIVE:	Nixon & Vanderhye	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	24 Drawing Figure(s); 21 Drawing Page(s)	
LINE COUNT:	1492	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 23 USPATFULL

TI Salts of tetracyclines

AB A salt of sucrose-octa-O-sulfonic acid and a tetracycline useful in inhibiting protein synthesis of bacteria.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 96:65545 USPATFULL

TITLE: Salts of tetracyclines

INVENTOR(S): Koch, Torben, Copenhagen, Denmark
Dyrsting, Hjarne, Virum, Denmark

PATENT ASSIGNEE(S): A/S Dumex (Dumex Ltd.), Copenhagen, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5538954		19960723
APPLICATION INFO.:	US 1994-265193		19940624 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Peselev, Elli		
LEGAL REPRESENTATIVE:	Watov & Kipnes		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1,5,7		
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	586		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 9 OF 23 USPATFULL
TI Anti-inflammatory compounds and compositions
AB Multivalent metal ion complexes of a polysulfate of xylan having glycosidically linked D-glucuronyl side chains or derivatives thereof are provided, together with therapeutic compositions thereof having anti-inflammatory activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 95:105830 USPATFULL
TITLE: Anti-inflammatory compounds and compositions
INVENTOR(S): Cullis-Hill, David, Bondi Junction, Australia
Ghosh, Peter, Fairlight, Australia
PATENT ASSIGNEE(S): Arthropharm Pty Limited, Bondi Junction, Australia
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5470840		19951128
APPLICATION INFO.:	US 1992-903081		19920610 (7)
RELATED APPLN. INFO.:	Division of Ser. No. US 1989-423455, filed on 19 Sep 1989, now patented, Pat. No. US 5145841		

	NUMBER	DATE
PRIORITY INFORMATION:	AU 1987-951	19870319
	AU 1987-2478	19870615
	AU 1987-5819	19871209
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Robinson, Douglas W.	
ASSISTANT EXAMINER:	Peselev, Elli	
LEGAL REPRESENTATIVE:	Nixon & Vanderhye	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1,7	
NUMBER OF DRAWINGS:	24 Drawing Figure(s); 23 Drawing Page(s)	
LINE COUNT:	1338	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 10 OF 23 USPATFULL
TI High molecular mass N,O-sulphated heparosans, process for their preparation and the pharmaceutical compositions which contain them
AB The subject of the invention is new high molecular mass N,O-sulphated heparosans consisting of chains or of a mixture of chains having a molecular mass of between 1.5.times.10.sup.4 and 4.0.times.10.sup.6 D, characterized by a repeating disaccharide structure of formula I:
##STR1## in which E represents, in 0 to 80% of the disaccharide units
of the said N,O-sulphated heparosan, an acetyl group and, in the remaining disaccharide units, a sulphate group and optionally a hydrogen atom, G represents a hydrogen atom and a sulphate group, and the pharmaceutically acceptable salts of the said N,O-sulphated heparosans.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 95:7963 USPATFULL
TITLE: High molecular mass N,O-sulphated heparosans, process for their preparation and the pharmaceutical compositions which contain them
INVENTOR(S): Lormeau, Jean-Claude, Kremlin Bicetre, France
Chevallier, Bruno, Villejuif, France
Salome, Marc L. V., Castanet-Tolosan, France
PATENT ASSIGNEE(S): Sanofi, Elf, Paris, France (non-U.S. individual)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: 5384398 19950124
 APPLICATION INFO.: 1994-191450 19940203)
 RELATED APPLN. INFO.: Division of Ser. No. US 1992-983371, filed on 30 Nov
 1992, now patented, Pat. No. US 5314876

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1991-14725	19911128
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Lilling, Herbert J.	
LEGAL REPRESENTATIVE:	Wegner, Cantor, Mueller & Player	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1818	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 11 OF 23 USPATFULL
 TI Sulphated polysaccharides, anticoagulant agent and anticomplementary agent obtained from brown algae fucuses and method of obtaining same
 AB The invention relates to sulphated polysaccharides obtained from fucuses extracted from pheophyceae. The molecular weight of these polysaccharides is greater than 5 and less than 40 Kda; their sulphur content is greater than that of the original fucus and they contain less than 0.15% of contaminant proteins. Applications as anticoagulant and anticomplementary agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 ACCESSION NUMBER: 94:51520 USPATFULL
 TITLE: Sulphated polysaccharides, anticoagulant agent and anticomplementary agent obtained from brown algae fucuses and method of obtaining same
 INVENTOR(S): Colliec, Sylvia, Paris, France
 Bretaudiere, Jacqueline, Paris, France
 Durand, Patrick, Reze, France
 Fischer, Anne-Marie, Paris, France
 Jozefonvicz, Jacqueline, Lamorlaye, France
 Kloareg, Bernard, Saint-Pol-De-Leon, France
 Vidal, Catherine, Paris, France
 PATENT ASSIGNEE(S): Institut Francais de Recherche pour l'Exploitation de la Mer-IFREMER, Issy-Les-Moulineaux, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5321133		19940614
	WO 9015823		19901227
APPLICATION INFO.:	US 1992-778220		19920116 (7)
	WO 1990-FR420		19900613
			19920116 PCT 371 date
			19920116 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1989-7857	19890614
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Griffin, Ronald W.	
LEGAL REPRESENTATIVE:	Bell, Seltzer, Park & Gibson	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	

NUMBER OF DRAWINGS: 3 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 821
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 12 OF 23 USPATFULL

TI High molecular mass N,O-sulphated heparosans, process for their preparation and the pharmaceutical compositions which contain them
AB The subject of the invention is new high molecular mass N,O-sulphated heparosans consisting of chains or of a mixture of chains having a molecular mass of between 1.5.times.10.sup.4 and 4.0.times.10.sup.6 D, characterised by a repeating disaccharide structure of formula I: ##STR1## in which E represents, in 0 to 80% of the disaccharide units
of the said N,O-sulphated heparosan, an acetyl group and, in the remaining disaccharide units, a sulphate group and optionally a hydrogen atom, G represents a hydrogen atom and a sulphate group, and the pharmaceutically acceptable salts of the said N,O-sulphated heparosans.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 94:44617 USPATFULL
TITLE: High molecular mass N,O-sulphated heparosans, process for their preparation and the pharmaceutical compositions which contain them
INVENTOR(S): Lormeau, Jean-Claude, Kremlin Bicetre, France
Chevallier, Bruno, Villejuif, France
Salome, Marc L. V., Castanet-Tolosan, France
PATENT ASSIGNEE(S): Elf Sanofi, Paris, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5314876		19940524
APPLICATION INFO.:	US 1992-983371		19921130 (7)

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1991-14725	19911128
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Lilling, Herbert J.	
LEGAL REPRESENTATIVE:	Wegner, Cantor, Mueller & Player	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1733	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 13 OF 23 USPATFULL

TI Antiviral compositions containing .alpha.-cyclodextrin sulfates alone and in combination with other known antiviral agents and glucocorticoids and methods of treating viral infections
AB The present invention is directed to antiviral compositions containing .alpha.-cyclodextrin sulfates alone and in combination with other known antiviral agents and glucocorticoids and methods of treating viral infections.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 93:50539 USPATFULL
TITLE: Antiviral compositions containing .alpha.-cyclodextrin sulfates alone and in combination with other known antiviral agents and glucocorticoids and methods of treating viral infections
INVENTOR(S): Anand, Rita, Rockville, MD, United States
Pitha, Joseph, Baltimore, MD, United States
PATENT ASSIGNEE(S): The United States of America as represented by the

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5221669		19930622
APPLICATION INFO.:	US 1991-687599		19910419 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rollins, John W.		
LEGAL REPRESENTATIVE:	Birch, Stewart, Kolasch & Birch		
NUMBER OF CLAIMS:	13		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	613		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 14 OF 23 USPATFULL

TI Anti-inflammatory compounds and compositions
AB Method for the treatment of arthritis, rheumatism and inflammation of connective tissue in which a multivalent metal ion substantially pure complex of xylan polysulphate, wherein the multivalent metal ion is selected from the group consisting of Ca.sup.2+, Mg.sup.2+, Cu.sup.2+ and Zn.sup.2+ is administered to a patient in need of such treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 92:74607 USPATFULL
TITLE: Anti-inflammatory compounds and compositions
INVENTOR(S): Cullis-Hill, David, Bondi Junction, Australia
Ghosh, Peter, Fairlight, Australia
PATENT ASSIGNEE(S): Arthropharm PTY. Limited, NSW, Australia (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5145841		19920908
	WO 8807060		19880922
APPLICATION INFO.:	US 1989-423455		19890919 (7)
	WO 1988-AU77		19880321
			19890919 PCT 371 date
			19890919 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	AU 1987-951	19870319
	AU 1987-2478	19870615
	AU 1987-5819	19871209
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Griffin, Ronald W.	
ASSISTANT EXAMINER:	Carson, Nancy S.	
LEGAL REPRESENTATIVE:	Nixon & Vanderhye	
NUMBER OF CLAIMS:	3	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	24 Drawing Figure(s); 23 Drawing Page(s)	
LINE COUNT:	1269	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 15 OF 23 USPATFULL

TI Depolymerization method of heparin
AB A method of depolymerizing heparin to obtain a heparin with low molecular weight provided with antithrombotic activity comprises treating a quarternary ammonium salt of heparin with a quarternary ammonium hydroxide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 901251 USPATFULL
TITLE: Depolymerization method of heparin
INVENTOR(S): Lopez, Lorenzo L., C/ Ferraz, No. 42 - 1.sup.o Dcha,
28008 Madrid, Spain

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4981955		19910101
APPLICATION INFO.:	US 1990-485756		19900226 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1988-212568, filed on 28 Jun 1988, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Griffin, Ronald W.		
ASSISTANT EXAMINER:	Webber, Pamela S.		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
LINE COUNT:	289		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 16 OF 23 USPATFULL

TI Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use

AB Peptide fragments of certain apolipoproteins have been found to be both immunogenic and capable of eliciting antibodies with highly apolipoprotein-specific immunoreactivity. These antibodies, in labeled and unlabeled form, as well as the labeled synthetic peptide fragments, are useful in the production of immunodiagnostic procedures and kits

for quantitating type-specific apolipoproteins. Both competitive assays and immunometric assays are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 90:87276 USPATFULL
TITLE: Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use
INVENTOR(S): Fareed, George, Los Angeles, CA, United States
Sen, Arup, Los Angeles, CA, United States
PATENT ASSIGNEE(S): International Genetic Engineering, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4970144		19901113
APPLICATION INFO.:	US 1986-905584		19860902 (6)
	WO 1985-US2569		19851226
			19860902 PCT 371 date
			19860902 PCT 102(e) date
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1984-688040, filed on 31 Dec 1984, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Marantz, Sidney		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 8 Drawing Page(s)		
LINE COUNT:	986		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 17 OF 23 USPATFULL

TI Purification of blood coagulation factor VIII by precipitation with sulfated polysaccharides

AB Efficient precipitation and removal of the proteins fibrinogen and fibronectin from blood plasma fractions, especially cryoprecipitate, while leaving high yields of blood coagulation factor VIII in the supernatant. This is achieved by the addition of at least 0.15 mg, preferably 0.3-0.9 mg, of a **sulphated polysaccharide**, especially heparin, per ml of buffered plasma fraction solution while maintaining the temperature of the solution during fibrinogen/fibronectin removal at more than 15.degree. C., preferably 20.degree.-35.degree. C. Lyophilised factor VIII preparation prepared from the factor VIII-rich supernatant product of the invention are suitable for heat treatment at, for example, 70.degree. C. for 24 hours to inactivate blood-born viruses without significant generation of insoluble denatured protein by-products.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 88:79161 USPATFULL
 TITLE: Purification of blood coagulation factor VIII by precipitation with sulfated polysaccharides
 INVENTOR(S): Winkelman, Lowell, Oxford, England
 PATENT ASSIGNEE(S): The Central Blood Laboratories Authority, Borehamwood, England (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4789733		19881206
	WO 8605190		19860912
APPLICATION INFO.:	US 1986-928178		19861117 (6)
	WO 1986-GB121		19860306
			19861117 PCT 371 date
			19861117 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1985-5882	19850307
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Schain, Howard E.	
LEGAL REPRESENTATIVE:	Nixon & Vanderhye	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
LINE COUNT:	692	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 18 OF 23 USPATFULL

TI Pharmaceutical compositions

AB Pharmaceutical compositions comprising mixtures of sodium polyacrylate and carbenoxolone sodium in a specified range of ratios have been found to exhibit synergistic effects in an in vivo test model for anti-ulcer or mucosal-protecting agents. Pharmaceutical compositions comprising mixtures of sodium polyacrylate and carbenoxolone in the range of ratios

are described for use in the treatment of gastritis or of gastro-duodenal ulcers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 87:20526 USPATFULL
 TITLE: Pharmaceutical compositions
 INVENTOR(S): Dettmar, Peter W., Welwick, England
 PATENT ASSIGNEE(S): Reckitt & Colman Products Limited, Great Britain (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4652446		19870324

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1983-23624	19830902
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Waddell, Frederick E.	
LEGAL REPRESENTATIVE:	Bacon & Thomas	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
LINE COUNT:	437	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 19 OF 23 USPATFULL

TI Process for obtaining a plasminogen activator

AB The present invention relates to an improved process for the preparation of plasminogen activator.

This is a process for separating a plasminogen activator according to U.S. Pat. No. 3,998,947 characterized in that it comprises at least the following stages:

(i) selective adsorption of the said activator on a support with specific affinity comprising soluble fragments of fibrin covalently bonded to an insoluble matrix; and

(ii) elution of the activator from the fibrin bearing the adsorbed activator.

The plasminogen activator obtained is useful in the prevention and treatment of thrombosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 82:6930 USPATFULL
TITLE: Process for obtaining a plasminogen activator
INVENTOR(S): Dussourd d'Hinterland, Lucien, Castres, France
Normier, Gerard, Castres, France
PATENT ASSIGNEE(S): Pierre Fabre S.A., Paris, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4314994		19820209
APPLICATION INFO.:	US 1980-172029		19800724 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1979-19432	19790727
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Rosen, Sam	
LEGAL REPRESENTATIVE:	Levine, Alan H.	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1,8	
LINE COUNT:	309	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 20 OF 23 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
TI New antiviral **sulphated polysaccharide(s)** - isolated from rhodophyceae, for treating AIDS, ARC and related syndromes.
AN 1993-199249 [25] WPIDS
AB GB 2262531 A UPAB: 19931116

A **sulphated polysaccharide** (I) which has a common backbone of the agaroid-type, composed of alternating beta (1-4) D-galactose and alpha (1-3) L-galactose repeating units and its salt are claimed. (I) has the following properties after being purified to homogeneity by anion exchange chromatography by application of an increasing NaCl gradient, dialysed exhaustively against distilled water and freeze-dried: (a) elementary analysis: 20-35 wt.% C, 3.2-5.5 wt.% H, less than 1 wt.% N and more than 8 wt.% S, when calculated as an

anhydrous

cpd.; (b) mol.wt. of upto 10,000 kD as measured by high performance size exclusion chromatography; (c) soluble in water, in aq. phosphate buffers at pH 1-13 and in aq. solvents contg. upto 20 vol.% of a water-soluble alcohol but insoluble in benzene, CHCl₃, ethyl ether and in

aq.-alcoholic

solns. contg. more than 80 vol.% MeOH or EtOH and 1g/l NaCl; (d) soluble in water in the presence of BaCl₂, but, after being hydrolysed for 3 hrs. at 120 deg.C. in aqs. 2M HCl, it gives a ppt., of BaSO₄ upon addn. of BaCl₂; (e) more than 90 molar % of the total monosaccharidic units are galactose and 3,6-anhydrogalactose residues which are opt. substd.; (f) more than 30 molar % of the total monosaccharidic units consist of 4-0-linked alpha-L-galactopyranosidic residues which can carry substituents at positions 2,3 and/or 6; (g) more than 40 molar % of the total monosaccharidic units consist of 3-0-linked beta-D-galactopyranosidic residues which can carry substituents at positions 2,4 and/or 6; (h) more than 40 molar % of the total monosaccharidic units consist of 4-0-linked alpha-L-galactopyranosidic residues which can carry substituents at

positions

2,3 and 6, plus 4-0-linked 3,6-anhydro-alpha-L-galactopyranosidic residues which can carry a substituent at position 2; (i) pyruvate (1-carboxyethylidene) gps., linked as cyclic ketals bridging 0-4 and 0-6 of beta-D-galactopyranosidic residues, occur as substituents in less than 10 molar % of the total monosaccharidic units; (j) the molar ratio of methyl ether gp. substituents per monosaccharide unit does not exceed 0.3:1; (k) sulphate hemiester gps. can be present as substituents at positions 2,4 and

6

of the beta-D-galactopyranosidic residues, at positions 2,3 and 6 of the alpha-L-galactopyranosidic residues and at position 2 of the 3,6-anhydro-alpha-L-galactopyranosidic residues, and the total degree of sulphation is always greater than 0.6; (l) the contribution of sulphate hemiester gps. at positions 2 and 4 to the total degree of sulphation is always greater than 0.3.

USE - (I) has antiviral activity against DNA and RNA viruses such as respiratory syncytial virus, herpes simplex virus (HSV), vaccinia virus, influenza virus and partic. HIV.

Dwg.0/0

ABEQ DE 4242813 A UPAB: 19931116

A **sulphated polysaccharide** (I) which has a common backbone of the agaroid-type, composed of alternating

beta (1-4) D-galactose

and alpha (1-3) L-galactose repeating units and its salts are claimed. (I) has the following properties after being purified to homogeneity by anion exchange chromatography by application of an increasing NaCl gradient, dialysed exhaustively against distd. water and freeze-dried: (a) elementary analysis: 20-35 wt.% C, 3.2-5.5 wt.% H, less than 1 wt.% N and more than 8 wt.% S, when calculated as an anhydrous cpd.; (b) mol. wt. of up to 10,000 kD as measured by high performance size exclusion chromatography; (c) soluble in water, in aqs. phosphate buffers at pH

1-13

and in aqs. solvents contg. up to 20 vol.% of a water-soluble alcohol but insoluble in benzene, CHCl₃, ethyl ether and in aq.-alcohols solns.c

ontg.

more than 80 vol.% MeOH or EtOH and 1g/l NaCl; (d) soluble in water in

the

presence of BaCl₂, but, after being hydrolysed for 3 hrs. at 120 deg. C

in

aq. 2M HCl, it gives a ppte. of BaSO₄ upon addn. of BaCl₂; (e) more than 90 molar% of the total monosaccharidic units are galactose and 3,6-anhydrogalactose residues which are opt. substd.; (f) more than 30 molar % of the total monosaccharidic units consist of 4-O-linked alpha-L-lactopyranosidic residues which can carry substituents at positions 2,3 and/or 6; (g) more than 40 molar % of the total monosaccharidic units consist of 3-O-linked beta-D-galactopyranosidic residues which can carry substituents at positions 2,4 and/or 6; (h) more than 40 molar % of the

total

monosaccharidic units consist of 4-O-linked alpha-L-galactopyranosidic residues which can carry substituents at positions 2,3 and 6, plus

4-O-linked

3,6-anhydro-alpha-L-galactopyranosidic residues which can carry a substituent at position 2; (i) pyruvate (1-carboxyethylidene) gps., linked

as

cyclic ketals bridging O-4 and O-6 of beta-D-galactopyranosidic residues, occur as substituents in less than 10 molar% of the total monosaccharidic units; (j) the molar ratio of methyl ether gp. substituents per monosaccharide unit does not exceed 0.3:1; (k) sulphate hemiester gps.

can

be present as substituents at positions 2,4 and 6 of the beta-D-galactopyranosidic residues, at positions 2,3 and 6 of the alpha-L-galactopyranosidic residues and at position 2 of the 3,6-anhydro-alpha-L-galactopyranosidic residues, and the total degree of sulphation is always greater than 0.6; (l) the contribution of sulphate hemiester gps. at positions 2 and 4 to the total degree of sulphation is always greater than 0.3.

USE - (I) has antiviral activity against DNA and RNA viruses such as respiratory syncytial virus, herpes simplex virus, (HSV), vaccinia virus, influenza virus and partic. HIV.

Dwg. 0/3

ABEQ GB 2262531 B UPAB: 19960108

A **sulphated polysaccharide** which has a common backbone of the agaroid-type, composed of alternating Beta(1-greater than 4) D-galactose and Alpha(1-greater than 3)L-galactose repeating units, and which has the following properties after being purified to homogeneity by anion exchange chromatography by application of an increasing sodium chloride gradient, dialysed exhaustively against distilled water, and freeze-dried: (a) elementary analysis: 20-35 % by weight carbon, 3.2-5.5

%

by weight hydrogen, less than 1% by weight nitrogen and more than 8 % by weight sulphur, when calculated as anhydrous compound; (b) molecular weight of up to 10000 kDa as measured by high performance size exclusion chromatography; (c) soluble in water, in aqueous phosphate buffers at pH

1

to 13 and in aqueous solvents containing up to 20% by volume of a water-soluble alcohol but insoluble in benzene, chloroform, ethyl ether and in aqueous-alcoholic solutions containing more than 80% by volume methyl- or ethyl-alcohol and 1 g/l of sodium chloride; (d) soluble in water in the presence of barium chloride, but, after being hydrolysed for 3 hrs at 120 degC in aqueous 2 M hydrochloric acid, it gives a **precipitate** of barium sulphate upon addition of barium chloride;

(e) more than 90 molar % of the total monosaccharidic units are galactose and 3,6-anhydrogalactose residues which are unsubstituted or substituted; (f) more than 30 molar % of the total monosaccharidic units consist of 4-O-linked alpha-L-galactopyranosidic residues which can carry

substituents

at positions 2, 3 and/or 6; (g) more than 40 molar % of the total monosaccharidic units consist of 3-O-linked beta-D-galactopyranosidic residues which can carry substituents at positions 2, 4 and/or 6; (h)

more

than 40 molar % of the total monosaccharidic units consist of 4-O-linked alpha-L-galactopyranosidic residues which can carry substituents at positions 2, 3 and 6, plus 4-O-linked 3,6-anhydro-alpha-L-

galactopyranosidic residues which can carry a substituent at position 2; (i) pyruvate (1-carboxyethylidene) groups, linked as cyclic ketals bridging 0-4 and 0-6 of beta-D-galactopyranosidic residues, occur as substituents in less than 10 molar % of the total monosaccharidic units; (j) the molar ratio of methyl ether group substituents per monosaccharide unit does not exceed 0.3:1; (k) sulphate hemiester groups can be present as substituents at positions 2, 4 and 6 of the beta-D-galactopyranosidic residues, at positions 2, 3 and 6 of the alpha-L-galactopyranosidic residues and at position 2 of the 3,6-anhydro-alpha-L-galactopyranosidic residues, and the total degree of sulphation is always greater than 0.6.
Dwg.0/1

ACCESSION NUMBER: 1993-199249 [25] WPIDS
DOC. NO. CPI: C1993-088149
TITLE: New antiviral **sulphated polysaccharide**
(s) - isolated from rhodophyceae, for treating AIDS, ARC and related syndromes.
DERWENT CLASS: B04
INVENTOR(S): CORIGLI, R; RIVOLA, G; UNGHERI, D; VENTRELLA, G
PATENT ASSIGNEE(S): (FARM) FARMITALIA ERBA SRL CARLO
COUNTRY COUNT: 4
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
GB 2262531	A	19930623	(199325)*		54
DE 4242813	A1	19930624	(199326)		17
JP 05271306	A	19931019	(199346)		18
GB 2262531	B	19951206	(199601)		
IT 1256659	B	19951212	(199627)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
GB 2262531	A	GB 1991-26761	19911217
DE 4242813	A1	DE 1992-4242813	19921217
JP 05271306	A	JP 1992-334561	19921215
GB 2262531	B	GB 1991-26761	19911217
IT 1256659	B	IT 1992-MI2851	19921214

PRIORITY APPLN. INFO: GB 1991-26761 19911217

L7 ANSWER 21 OF 23 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
TI New Micrococcus and Arthrobacter strain AT-25 - used for producing new **sulphated polysaccharide** DF-4639 useful as antithrombotic.
AN 1988-363983 [51] WPIDS
CR 1981-53982D [30]
AB JP 63273471 A UPAB: 19930923
Strain AT-25 (FERM P-5255 and FERM BP-1357) is new. The strain AT-25 is tentatively classified as Micrococcus sp. AT-25 (FERM P-5255) and then as Arthrobacter sp. AT-25 (FERM BP-1357). In order to produce DF-4639, the strain AT-25 is cultured in a medium contg. sulphate such as sodium sulphate and ammonium sulphate at 25-37 deg. C and at pH 6.5-8.5 for 50-200 hours under aerobic condition. DF-4639 is collected from the culture of AT-25 as follows: To the culture filtrate cetylpyridinium chloride is added and the **precipitate** is dissolved in 3M NaCl containing 10% ethanol. Ethanol is added to the soln. and the **precipitate** is washed with ethanol and acetone. The **precipitate** is dissolved in water and the pH is lowered to 1.0 by HCl. After removing the precipitate at 5 deg. C, the soln. is neutralised and cetyltrimethylammonium bromide soln. is added to **precipitate** active substance. After removing nucleic acids by

suspending the precipitate in 1M NaCl soln. the remaining ppte. is dissolved in 3M NaCl contg. 10% ethanol at 50 deg. C Ethanol is added

to

ppte. active substance and the **precipitate** is washed with ethanol and acetone. Thus DF-4639 is obtained as a white powder. DF-4639 is recovered from the cell body in a similar way.

USE/ADVANTAGE - The strain AT-25 produces an antithrombotic cpd. DF-4639, a new substance whose main component is a **sulphated polysaccharide**. DF-4639 exhibits the same or higher fibrinogenolysis-inducing activity than heparin, another **sulphated polysaccharide** derived from animals. DF-4639 is an antithrombotic drug, has lipoprotein lipase activating activity, anti-cancer activity

and

phylaxis activity.

0/0

ACCESSION NUMBER: 1988-363983 [51] WPIDS
CROSS REFERENCE: 1981-53982D [30]
DOC. NO. CPI: C1988-161043
TITLE: New Micrococcus and Arthrobacter strain AT-25 - used for producing new **sulphated polysaccharide** DF-4639 useful as antithrombotic.
DERWENT CLASS: B04 D16
PATENT ASSIGNEE(S): (DAUC) DAIICHI SEIYAKU CO
COUNTRY COUNT: 1
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
JP 63273471	A	19881110	(198851)*		6
JP 02007631	B	19900220	(199011)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
JP 63273471	A	JP 1988-83710	19870430

PRIORITY APPLN. INFO: JP 1979-144895 19791108; JP 1988-83710 19870430

L7 ANSWER 22 OF 23 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
TI Purifying blood coagulation factor VIII - by adding **sulphated polysaccharide** to ppte. fibrinogen and fibronectin.
AN 1986-240546 [37] WPIDS
AB GB 2172000 A UPAB: 19930922
Method of preparing a VIII-contg. prepn. includes the steps of precipitating fibrinogen and fibronectin from a buffered soln. of a VIII-contg. blood plasma fraction by the addition of a **sulphated polysaccharide** (SPS) and removing the ppte. from the VIII-contg. supernatant. The amt. of SPS added to the plasma fraction is at least

0.15

mg of SPS per ml of the buffered soln. and the temp. of the buffered soln.

during the pptn. and removal of fibrinogen and fibronectin is maintained at more than 15 deg.C. Pref. the SPS is added at 0.44-0.88 mg/ml at 25-30 deg.C. The SPS is pref. a heparinoid selected from mucopolysaccharide, polysulphates, pentosan polysulphate, chondroitin sulphate and dextran sulphate.

USE/ADVANTAGE - The VIII is used to treat individuals suffering from classical haemophilia. Highly efficient fibrinogen removal is achieved. The amt. of buffer soln. required to make up the buffered plasma fraction soln. for pptn. is less. Precipitating of fibrinogen is maximal after about 5 mins. mixing and no significant further pptn. of factor VIII

occurs up to at least 20 mins..

0/0

ABEQ EP 215050 B UPAB: 930922

A method of preparing a FVIII-containing preparation which includes the steps of precipitating fibrinogen and fibronectin from a buffered solution

of a blood plasma fraction selected from cryoprecipitate and FVIII-containing purified concentrates derived therefrom by the addition of a SPS, and removing the **precipitate** from the FVIII-containing supernatant. characterised in that the amount of SPS added to the plasma fraction is at least 0.15 mg of SPS per ml of the buffered solution and further characterised in that the temperature of the buffered solution during the precipitation and removal of the fibrinogen and fibronectin is maintained at more than 15 deg.C.

ABEQ GB 2172000 B UPAB: 19930922

Method of preparing a VIII-contg. prepn. includes the steps of precipitating fibrinogen and fibronectin from a buffered soln. of a VIII-contg. blood plasma fraction by the addition of a **sulphated polysaccharide** (SPS) and removing the ppte. from the VIII-contg. supernatant. The amt. of SPS added to the plasma fraction is at least

0.15

mg of SPS per ml of the buffered soln. and the temp. of the buffered soln.

during the pptn. and removal of fibrinogen and fibronectin is maintained at more than 15 deg.C. Pref. the SPS is added at 0.44-0.88 mg/ml at 25-30 deg.C. The SPS is pref. a heparinoid selected from mucopolysaccharide, polysulphates, pentosan polysulphate, chondroitin sulphate and dextran sulphate.

USE/ADVANTAGE - The VIII is used to treat individuals suffering from classical haemophilia. Highly efficient fibrinogen removal is achieved. The amt. of buffer soln. required to make up the buffered plasma fraction soln. for pptn. is less. Precipitating of fibrinogen is maximal after about 5 mins. mixing and no significant further pptn. of factor VIII occurs up to at least 20 mins..

0/0

ABEQ US 4789733 A UPAB: 19930922

Purificn. of blood clotting factor VIII comprises pptn. of fibrinogen and

fibronectin from buffered blood plasma fraction with a **sulphated polysaccharide** (0.15-3.00 mg per cm³ plasma) at above 15 deg.C; and removal of the ppte to leave factor VIII in the supernatant liquor.

USE - The prods. are therapeutics for haemophilic patients.

ABEQ JP 93043688 B UPAB: 19931116

Purificn. of blood clotting factor VIII comprises pptn. of fibrinogen and fibronectin from buffered blood plasma fraction with a **sulphated polysaccharide** (0.15-3.00 mg per cm³ plasma) at above 15 deg.C; and removal of the ppte. to leave factor VIII in the supernatant liquor.

USE - The prods are therapeutics for haemophilic patients.

(J62502116-W)

ACCESSION NUMBER: 1986-240546 [37] WPIDS

DOC. NO. CPI: C1986-103406

TITLE: Purifying blood coagulation factor VIII - by adding **sulphated polysaccharide** to ppte. fibrinogen and fibronectin.

DERWENT CLASS: B04

PATENT ASSIGNEE(S): (BLOO-N) CENT BLOOD LAB AUTH; (WINK-I) WINKELMAN L;
(BLOO-N) CENT BLOOD LAB AUTHORITY

COUNTRY COUNT: 15

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
GB 2172000	A	19860910	(198637)*		9
WO 8605190	A	19860912	(198638)	EN	

RW: AT BE CH DE FR GB IT LU NL SE
 W: AU JP US
 ZA 8601731 A 19 909 (198649)
 AU 8655435 A 19860924 (198650)
 EP 215050 A 19870325 (198712) EN
 R: AT BE CH DE FR IT LI LU NL SE
 JP 62502116 W 19870820 (198739)
 US 4789733 A 19881206 (198851)
 GB 2172000 B 19890628 (198926)
 EP 215050 B 19910206 (199106)
 R: AT BE CH DE FR IT LI LU NL SE
 DE 3677436 G 19910314 (199112)
 JP 05043688 B 19930702 (199329) 10

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
GB 2172000	A	GB 1986-5556	19860306
WO 8605190	A	WO 1986-GB121	19860306
ZA 8601731	A	ZA 1986-1731	19860307
EP 215050	A	EP 1986-901470	19860306
US 4789733	A	US 1986-928178	19861117
JP 05043688	B	JP 1986-501448	19860306
		WO 1986-GB121	19860306

FILING DETAILS:

PATENT NO	KIND	PATENT NO
JP 05043688	B Based on Based on	JP 62502116 WO 8605190

PRIORITY APPLN. INFO: GB 1985-5882 19850307; GB 1986-5556
19860306

L7 ANSWER 23 OF 23 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
 TI Anti haemophilic factor VIII compsns. prodn. from plasma fractions - by
 prepn. of ballast proteins with **sulphated polysaccharide**
 and subsequent pptn. of factor VIII at high ionic strength.
 AN 1984-302237 [49] WPIDS
 AB EP 127603 A UPAB: 19930925
 Prodn. of a factor VIII (anti-haemophilic factor, AHF) prepn. has
 specific
 activity of at least 1.5 factor VIII units/mg protein, an immunoglobulin
 G
 (IgG) content of 15-30 mg/1000 units factor VIII and a fibrinogen content
 of 20-40 mg/100 units factor VIII, in which (A) a factor VIII-contg.
 plasma fraction is dissolved in a buffer soln. and undesired proteins are
 pptd. at pH 6-7 in the presence of **sulphated**
polysaccharide; (B) the ppte. is discarded and the factor
 VIII-contg. supernatant is treated with a protein precipitant in the
 presence of salts at pH 6-7; and (C) the resulting factor VIII-contg.
 ppte. is dissolved and an antithrombin III/heparin or antithrombin
 III/heparinoid complex is optionally added.
 ADVANTAGE - Economical and high-yield process giving a factor VIII
 prepn. with high specific activity and low IgG content. Solubility of the
 product after lyophilisation is good (reconstitution time not more than
 0.5-4 mins.).
 0/0
 ABEQ EP 127603 B UPAB: 19930925
 Method for producing a Factor VIII (AHF) containing preparation having a
 specific activity of at least 1.5 units of Factor VIII/mg protein as well
 as a portion of immunoglobulin G(IgG) of from 15 to 30 mg/100 units of

Factor VIII and a portion of fibrinogen of from 20 to 40 mg/100 units of Factor VIII, by dissolution of a Factor VII containing plasma fraction in a buffer solution, purification of the solution by precipitation of undesired proteins at a pH in the neutral range, concentration of the Factor VIII containing residue and processing of the concentrate into stable form, characterised in that the precipitation of undesired

proteins

is carried out in the presence of **sulphated polysaccharide** at a pH of from 6 to 7, whereupon, after discarding the **precipitate**, the Factor VIII containing supernatant is treated with a protein precipitating agent in the presence of salts at a pH of from 6 to 7 so as to obtain a Factor VIII containing **precipitate**, which Factor VIII containing **precipitate** is dissolved, and if desired, an antithrombin III-heparin complex or an antithrombin III-heparinoid complex is added to the final product.

ABEQ US 4522751 A UPAB: 19930925

A prepn. contg. Factor VIII (AHF) is obtd. from a plasma fraction by (a) dissolving the plasma fraction in a buffer soln. contg. a **sulphated polysaccharide** (pref. mucopolysaccharide polysulphuric acid ester, pentosan polysulphate, or dextran sulphate) at pH approx. 7; (b) lowering pH to 6.0-6.4 and adjusting temp. to 0.25

(4-8)

deg.C to opt. undesired proteins and to obtd. a supernatant liq. contg. Factor VIII; (c) adding at least 1 of: glycine, sodium chloride and

sodium

citrate to the supernatant liq. to maintain most of the immunoglobulins

in

soln.; (d) adding a protein-pptng. agent (pref. ethanol) to opt. Factor VIII; (e) dissolving Factor VIII opt. is a solvent, pref. a glycine-citrate-NaCl buffer. An antithrombin III-heparin (or heparinoid) complex may be added to the soln. which is then processed. Albumin may be added to the final prod. for stabilisation.

Prods. have a specific activity of 1.5 units of Factor VIII/mg protein, immunoglobulin G (IgG) of 15-30 mg/1000 units of Factor VIII,

and

20-40 mg/100 units of Factor VIII.

ACCESSION NUMBER: 1984-302237 [49] WPIDS

DOC. NO. CPI: C1984-128648

TITLE: Anti haemophilic factor VIII compsns. prodn. from plasma fractions - by prepn. of ballast proteins with **sulphated polysaccharide** and subsequent pptn. of factor VIII at high ionic strength.

DERWENT CLASS: B04

INVENTOR(S): LINNAU, Y; SCHWARZ, O

PATENT ASSIGNEE(S): (IMMO) IMMUNO CHEM AG

COUNTRY COUNT: 15

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
EP 127603	A	19841205	(198449)*	GE	13
R: AT BE CH DE FR GB IT LI NL SE					
JP 59222420	A	19841214	(198505)		
DK 8402415	A	19841121	(198508)		
US 4522751	A	19850611	(198526)		
AT 8301858	A	19850615	(198531)		
ES 8505822	A	19851016	(198604)		
CA 1225331	A	19870811	(198736)		
EP 127603	B	19890104	(198902)	GE	
R: AT BE CH DE FR GB IT LI NL SE					
DE 3475871	G	19890209	(198907)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
EP 127603	A	EP 1984-890088	19840510
JP 59222420	A	JP 1984-101636	19840519
US 4522751	A	US 1984-611638	19840518
EP 127603	B	EP 1984-890083	19840510

PRIORITY APPLN. INFO: AT 1983-1858 19830520

=> s antihemophilic factor () method () fibronectin prepration

9 FILES SEARCHED...

L8 0 ANTIHEMOPHILIC FACTOR (W) METHOD (W) FIBRONECTIN PREPRATION